JH509

JH509 is an aerosolized therapeutic candidate developed by Genova Inc. for the treatment of mild COVID-19. It is administered via inhalation using a mesh nebulizer, a delivery method designed to target the respiratory tract directly, where SARS-CoV-2 replication is most active in early-stage disease. The drug is currently being evaluated in a Phase III double-blind, randomized, placebo-controlled clinical trial in Japan (jRCT2031210448) to assess its efficacy and safety in non-hospitalized adult outpatients. The primary endpoint of the study is the change in total clinical symptom scores. While the specific molecular mechanism (e.g., whether it is a small molecule antiviral or a neutralizing antibody) has not been widely disclosed in public literature, its development focus is on reducing symptom severity and duration in the outpatient setting.